Glaucoma is a blinding disease caused by damage to the optic nerve, leading to permanent vision loss. The main risk factor is ...

As Glaucoma Awareness Month highlights evolving practice, specialists describe how artificial intelligence, sustained drug ...

An OU Health eye specialist explains who is most at risk, why symptoms are rare, and how early exams can prevent permanent ...

Smith, MD, of Glaucoma Associates of Texas, in Dallas, sat down with the Eye Care Network to reflect on how glaucoma care ...

Bausch + Lomb has partnered with the glaucoma community once again, launching its fifth annual fundraising challenge and ...

The researchers concluded that there is likely a lingering influence of the historical IOP cutoff of 22 mm Hg when it comes to decision-making in clinicians. “It is essential for clinicians to ...

Shared insight on how the use and sequencing of therapies for glaucoma will evolve in coming years. Neil Minkoff, MD: Where do we see glaucoma therapy going in the next 24 to 36 months, due to ...

AND JESS, YOU SAY THIS COULD BE A GAME CHANGER. YOU KNOW, IT REALLY CAN. ABOUT 3 MILLION AMERICANS HAVE GLAUCOMA AND THIS NEW TREATMENT IS BASICALLY AN IMPLANTABLE DRUG FOR THE EYE. AND DOCTORS SAY IT ...

Looking back, glaucoma specialists like Dr. Christine Funke of Barnet Dulaney Perkins Eye Center can remember a time not long ago when treatment options for the eye condition were greatly limited.

OT dives into a key topic in the education programme at 100% Optical 2026. This week: Sana Hamid shares insight into her ...

Glaucoma often described as the “silent thief of sight” affects millions in India with most cases remaining undiagnosed.